AstraZeneca

News

AZ's new COPD inhaler Bevespi Aerosphere approved in EU

AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in Europe, as a maintenance treatment for chronic obstructive pulmonary disease (COPD).

News

AZ/Merck & Co get new US use for ovarian cancer drug

After several disappointments this year AstraZeneca has ended 2018 on a positive note, gaining a new use for its ovarian cancer drug Lynparza in the US and a first approval in China for its

News

AZ begins liver cancer immunotherapy tie-up with AVEO

AstraZeneca has announced a collaboration with US biotech AVEO oncology to investigate a potential cancer immunotherapy combination in liver cancer.

Views & Analysis

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

AstraZeneca looks to CRISPR to boost success rates

Between 2005 and 2010 AstraZeneca‘s success rates for taking drugs from candidate nomination to phase III completion were at 4%, below an already-low industry standard of 5%.

News

AZ and CRUK team up to go all-in on CRISPR

AstraZeneca and Cancer Research UK are collaborating to launch a centre of excellence in genetic screening, cancer modelling and big data processing that will develop CRISPR technology to b

News

AZ's cancer drug fails again, Roche's rival gets new use

AstraZeneca’s immunotherapy Imfinzi has failed in another late stage study, while Roche’s rival Tecentriq combination has been approved in the sought-after first line lung cancer indication

AZ's new COPD inhaler Bevespi Aerosphere approved in EU

AZ/Merck & Co get new US use for ovarian cancer drug

AZ begins liver cancer immunotherapy tie-up with AVEO

AstraZeneca looks to CRISPR to boost success rates

AZ and CRUK team up to go all-in on CRISPR

AZ's cancer drug fails again, Roche's rival gets new use

CMS aims for broader GLP-1 access via federal programmes

How to meet your physicians where they are online

AstraZeneca

Editor's Picks